Table 1. Relationship between LINC00511 expression and clinicopathological features in breast cancer. Based on the median level of LINC00511 expression, patients were divided into a high expression group (N=48) and a low expression group (N=48).
| Variable | LINC00511 Expression | P valuea | ||
|---|---|---|---|---|
| Case, N | Low, N (%) | High, N (%) | ||
| Age, years | 0.537 | |||
| ≤50 | 42 | 23 (54.8) | 19 (45.2) | |
| >50 | 54 | 25 (46.3) | 29 (53.7) | |
| Tumor size, cm | 0.014 | |||
| ≤2 | 51 | 32 (62.7) | 19 (37.3) | |
| >2 | 45 | 16 (35.6) | 29 (64.4) | |
| LNM | 0.003 | |||
| No | 59 | 37 (62.7) | 22 (37.3) | |
| Yes | 37 | 11 (29.7) | 26 (70.3) | |
| TNM stage | 0.107 | |||
| I–II | 70 | 39 (55.7) | 31 (44.3) | |
| III–IV | 26 | 9 (34.6) | 17 (65.4) | |
| Molecular subtype | ||||
| Luminal like | 59 | 37 (62.7) | 22 (37.3) | 0.003 |
| HER-2 positive | 20 | 8 (40.0) | 12 (60.0) | |
| Triple negative | 17 | 3 (17.6) | 14 (82.4) | |
a, χ2 test. P<0.05 represents a significant difference. LNM, lymph node metastasis; TNM, tumor, node, metastasis.